Modality
Degrader
MOA
JAK1i
Target
CD20
Pathway
Ferroptosis
MGCSUMigraine
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
Jun 2018
→ Dec 2030
Phase 2Current
NCT05714788
2,591 pts·CSU
2018-06→2030-12·Terminated
NCT03097568
2,820 pts·MG
2023-02→2028-01·Recruiting
5,411 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-01-141.8y awayPh2 Data· MG
2030-12-244.7y awayPh2 Data· CSU
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Termina…
P2
Recruit…
Catalysts
Ph2 Data
2028-01-14 · 1.8y away
MG
Ph2 Data
2030-12-24 · 4.7y away
CSU
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05714788 | Phase 2 | CSU | Terminated | 2591 | NT-proBNP |
| NCT03097568 | Phase 2 | MG | Recruiting | 2820 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα |